IP Library Granted Patent US 7,241,879
Granted Patent B2
US 7,241,879 · App. 10/899,715 · Granted Jul 10, 2007

Immunoassays for anti-HCV antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,241,879
App. No.
10/899,715
Granted
Jul 10, 2007
Kind
B2
Abstract

HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.

Claims (35)

1. A polynucleotide comprising a coding sequence for a multiple epitope fusion antigen, wherein said multiple epitope fusion antigen the amino acid sequence of SEQ ID NO: 4, or an amino acid sequence with at least 80% sequence identity thereto which binds specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual, wherein said antibodies specifically bind with SEQ ID NO: 4.

2. The polynucleotide of claim 1 , wherein said polynucleotide comprises a coding sequence for a multiple epitope fusion antigen that comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 4 which binds specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual, wherein said antibodies specifically bind with SEQ ID NO: 4.

3. The polynucleotide of claim 1 , wherein said polynucleotide comprises a coding sequence for a multiple epitope fusion antigen that comprises an amino acid sequence with at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 4, which binds specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual, wherein said antibodies specifically bind with SEQ ID NO: 4.

4. The polynucleotide of claim 1 , wherein said polynucleotide comprises a coding sequence for a multiple epitope fusion antigen that consists of the amino acid sequence of SEQ ID NO: 4.

5. The polynucleotide of claim 1 , wherein said polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 3, or a nucleic acid sequence with at least 80% sequence identity thereto which encodes a polypeptide that binds specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.

6. The polynucleotide of claim 1 , wherein said polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 3, or a nucleic acid sequence with at least 90% sequence identity thereto which encodes a polypeptide that binds specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.

7. The polynucleotide of claim 1 , wherein said polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 3, or a nucleic acid sequence with at least 98% sequence identity thereto which encodes a polypeptide that binds specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.

8. A recombinant vector comprising:

(a) a polynucleotide according to claim 1 ;

(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.

9. A recombinant vector comprising:

(a) a polynucleotide according to claim 4 ;

(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.

10. A recombinant vector comprising:

(a) a polynucleotide according to claim 5 ;

(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.

11. A recombinant vector comprising:

(a) a polynucleotide according to claim 7 ;

(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.

12. A host cell transformed with the recombinant vector of claim 8 .

13. A host cell transformed with the recombinant vector of claim 9 .

14. A host cell transformed with the recombinant vector of claim 10 .

15. A host cell transformed with the recombinant vector of claim 11 .

16. A method of producing a recombinant multiple epitope fusion antigen comprising:

(a) providing a population of host cells according to claim 12 ; and

(b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.

17. A method of producing a recombinant multiple epitope fusion antigen comprising:

(a) providing a population of host cells according to claim 13 ; and

(b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.

18. A method of producing a recombinant multiple epitope fusion antigen comprising:

(a) providing a population of host cells according to claim 14 ; and

(b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.

19. A method of producing a recombinant multiple epitope fusion antigen comprising:

(a) providing a population of host cells according to claim 15 ; and

(b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Feb 6, 2017
From: DEUTSCHE BANK AG NEW YORK BRANK
To: GRIFOLS THERAPEUTICS INC.; GRIFOLS SHARED SERVICES NORTH AMERICA INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.
Reel/Frame 041638/0527 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME FROM GRIFOLS WORLDWIDE WAREHOUSE ANDOPERATIONS LIMITED TO GRIFOLS WORLDWIDE OPERATIONS LIMITED PREVIOUSLY RECORDED ON REEL 038979 FRAME 0981. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2016
From: GRIFOLS WORLDWIDE WAREHOUSE AND OPERATIONS LIMITED
To: GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 039204/0082 →
ASSIGNEE CHANGE OF ADDRESS Recorded Jun 13, 2016
From: GRIFOLS WORLDWIDE WAREHOUSE AND OPERATIONS LIMITED
To: GRIFOLS WORLDWIDE WAREHOUSE AND OPERATIONS LIMITED
Reel/Frame 038979/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2014
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
To: GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 034238/0731 →
CONFIRMATORY ASSIGNMENT Recorded Oct 2, 2014
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; NOVARTIS AG
To: GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 033886/0351 →
SECURITY AGREEMENT Recorded Feb 27, 2014
From: GRIFOLS INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS-CHIRON DIAGNOSTICS CORP.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032367/0001 →
CHANGE OF NAME Recorded May 29, 2007
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 019354/0230 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2007
From: CHIEN, DAVID Y.; ARCANGEL, PHILLIP; TANDESKE, LAURA; GEORGE-NASCIMENTO, CARLOS; COIT, DORIS; MEDINA-SELBY, ANGELICA
To: CHIRON CORPORATION
Reel/Frame 019273/0870 →
CHANGE OF NAME Recorded May 9, 2007
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 019273/0876 →